Skip to content
video poster image

Diagnostics Reimagined

Patented Versatile Platform for Biosensing: Tunable for detection of infections and diseases

Our Mission:

Life in Your Hand

Make Biosensor diagnostics affordable and available globally.

We have translated physical, chemical and biochemical sciences to electronics technology, using graphene and single-strand nucleic acids to achieve PCR-level precision. 

 


leafhand

What can we test for?

Screen Shot 2023-05-18 at 7.55.08 PM

Viruses

Covid-19, HIV1, HIV2, Hepatitis B, Hepatitis C, HTLV, West Nile Virus, Syphilis, Emerging Pandemics

istockphoto-1297146235-612x612

Genetic Defects 

Cancers, Diabetes, Autoimmunities, and Birth Defects

Screen Shot 2023-05-18 at 9.34.18 PM

Bacteria

Most bacterial infections from Malaria to Tuberculosis and Ulcers

HD-wallpaper-biohazard-blue-biohazard-gizzzi-labrano-black-blue-thumbnail

Toxins

 

4167740

Protein and Lipid Diseases

Heart Disease and Dementia

earth

What would you like to test for?

Am I sick or not sick?

With three simple steps, our biosensor technology is revolutionizing diagnostics

1. Place Sample on Chip

Our probes bind to the target within 10 minutes

2. Insert Chip Into Reader

Chip reader runs test on sample in 90 seconds

3. View Test Result

Positive/Negative result displayed
 
untitled (4)-Nov-13-2023-02-26-02-6665-AM

Our Groundbreaking Publications

Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor

Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor

 
Significance -

Our memories define us and connect us to others. Without them, we are lost. This is the driving force behind the global push to treat neurodegenerative diseases of the older population. How does one know they have a disease that has few outward symptoms until later stages? The current testing methods for diseases such as Alzheimer’s and Parkinson’s require a spinal tap and imaging tests such as MRI. This has made early detection of these diseases an incredible challenge. This work highlights a DNA aptamer-modified graphene field-effect transistor biosensor to detect unprocessed biomarker proteins in easily accessible biofluids derived from patients with Alzheimer’s disease, in pursuit of an affordable early-onset detection of neurodegenerative diseases.

Viruses of SARS-CoV-2 and its variants in saliva

Rapid self-test of unprocessed viruses of SARS-CoV-2 and its variants in saliva by portable wireless graphene biosensor

 
Significance - 
“Am I positive or negative?” Everyone wants to know the answer with speed and accuracy. Rapid and accurate at-home testing is the best defense against the COVID-19 pandemic and ensuing endemics. Current rapid tests are often imprecise, test for denatured and processed viral components, and lack specificity for new variants. We developed a simple at-home test using saliva swabs that answers “positive or negative” in minutes and transmits results to stakeholders. The test uses a DNA aptamer-derivatized graphene field-effect transistor (GFET) to detect unprocessed intact SARS-CoV-2 and its variants at levels as low as 7 to 10 viruses. This method is tunable and adaptable for early-stage detection of emerging viral infections as well as many diseases with accessible biofluids.
Highly specific SNP detection

Highly specific SNP detection using 2D graphene electronics and DNA strand displacement

 
Significance -

Our electrical sensor-based SNP detection technology, without labeling and without apparent cross-hybridization artifacts, allows fast, sensitive, and portable SNP detection with single-nucleotide resolution. The technology has a wide range of applications in digital and implantable biosensors and high-throughput DNA genotyping, with transformative implications for personalized medicine.

Patents

WO2025054610A1: Detection of dementia biomarkers using aptamer-modified graphene field-effect transistors

Detection of dementia biomarkers using aptamer-modified graphene field-effect transistors

 
Abstract -

Dementia is a brain disease which results in irreversible and progressive loss of cognition and motor activity. Despite global efforts, there are no simple and reliable diagnosis or treatment options. Embodiments of the disclosed technology provide an aptamer-based graphene field-effect transistor (GFET) biosensor platform that has high sensitivity and precision across a range of epidemiologically significant Alzheimer's disease and Parkinson's disease variants, and enables at-home and point-of-care (POC) testing for neurodegenerative diseases. An example method of detecting for detecting a molecular biomarker for dementia of a subject includes receiving a biological sample comprising the molecular biomarker for dementia, contacting the biological sample with a biosensor device comprising a GFET-based detection chip, and detecting a presence of the molecular biomarker for dementia in the biological sample.

WO2025024598A1: Biomarker detection using graphene field effect transistor sensor arrays and multichannel data acquisition

WO2025024598A1: Biomarker detection using graphene field effect transistor sensor arrays and multichannel data acquisition

 
Abstract -

We have developed a CMOS based low-power, multichannel data acquisition IC which interfaces directly with an array of GFET sensors for high-throughput, multiplexed evaluation of clinically-relevant biomarkers in a physiological sample. An example device for detecting a target analyte in a biological sample is provided. The device comprises an integrated circuit (IC) operable for evaluation of the biological samples for the target analyte, a two-dimensional array of graphene field effect transistor (GFET) sensor units where each of the GFET sensor units comprises a graphene surface with one or more probes attached to the graphene surface, and a control circuitry configured to simultaneously control a voltage clamping or a current clamping of each of the GFET sensor units. The biological sample is in contact with the one or more probes and the graphene surface, and the one or more probes bind to the target analyte present in the biological sample.

WO2022165532A1: Methods and devices for detecting a pathogen and its molecular components

Methods and devices for detecting a pathogen and its molecular components

 
Abstract - 
Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.
WO2017112941A1: Nano-sensors for nucleic acid detection and discrimination

Nano-sensors for nucleic acid detection and discrimination

 
Abstract -

Methods, systems, and nano-sensor devices are disclosed for detecting or discriminating nucleic acids with a single nucleotide resolution based on nucleic acid strand displacement. The detection can be made by time-lapse fluorescence measurements or by electro-based graphene FET, which can be combined with wireless communication to provide real-time transmission of the detected signals.

Contact Us